Molecular Genetics and Metabolism Reports (Jun 2018)

High incidence of low vitamin B12 levels in Estonian newborns

  • Karit Reinson,
  • Kadi Künnapas,
  • Annika Kriisa,
  • Mari-Anne Vals,
  • Kai Muru,
  • Katrin Õunap

Journal volume & issue
Vol. 15
pp. 1 – 5

Abstract

Read online

Vitamin B12 deficiency seems to be more common worldwide than previously thought. However, only a few reports based on data from newborn screening (NBS) programs have drawn attention to that subject. In Estonia, over the past three years, we have diagnosed 14 newborns with congenital acquired vitamin B12 deficiency. Therefore, the incidence of that condition is 33.8/100,000 live births, which is considerably more than previously believed. None of the newborns had any clinical symptoms associated with vitamin B12 deficiency before the treatment, and all biochemical markers normalized after treatment, which strongly supports the presence of treatable congenital deficiency of vitamin B12. During the screening period, we began using actively ratios of some metabolites like propionylcarnitine (C3) to acetylcarnitine (C2) and C3 to palmitoylcarnitine (C16) to improve the identification of newborns with acquired vitamin B12 deficiency.In the light of the results obtained, we will continue to screen the congenital acquired vitamin B12 deficiency among our NBS program. Every child with aberrant C3, C3/C2 and C3/C16 will be thoroughly examined to exclude acquired vitamin B12 deficiency, which can easily be corrected in most cases. Keywords: Newborn screening, Tandem mass spectrometry, Congenital vitamin B12 deficiency, Elevated propionylcarnitine